Shanghai, March 13, 2026 — Luye Pharma Group today announced a strategic partnership with Sinopharm Group Co. Ltd. (Sinopharm Group) and its subsidiary China National Medicines Corporation Ltd. (Sinopharm CNCM).

In this partnership, the three parties will collaborate with each other across product distribution, market access, and resource coordination focusing on multiple products of Luye Pharma including Mimeixin® (oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets). This partnership will allow them to combine the strength of Luye Pharma in pharmaceutical products and the strength of the Sinopharm family in supply chains to expand the reach of the quality products involved in the collaboration across China. The partnership is a milestone for Luye Pharma in its ongoing efforts to build an efficient commercial system.

Raising the bar for commercial partnership: Mimeixin as a start 

Mimeixin, the first product involved in this partnership, is indicated for the management of severe pain in adults that can only be effectively controlled with opioids. Naloxone, an opioid receptor antagonist contained in the product, reduces opioid-induced constipation (OIC) by blocking the binding of oxycodone to opioid receptors in the gut. Oxycodone/naloxone sustained-release tablet is China’s first oral analgesic to contain naloxone and remains the country’s only potent opioid-based painkiller that addresses OIC at its root. In 2025, Mimeixin was covered by China’s National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance, making the product more affordable. 

In recent years, driven by the growing number of surgeries and the need to receive standard treatments for cancer pain, the Chinese market for anesthetics and analgesics has been expanding. However, this is a market with high barriers and rigorous regulations. Sinopharm Group has over 130 subsidiaries qualified as regional distributors of anesthetics and antipsychotics, and Sinopharm CNCM in particular is qualified as a national distributor of anesthetics and antipsychotics with a dominant market share.

Given the regulatory requirements for anesthetics and antipsychotics and the demand for them in clinical practice, the three parties will work together to build a customized system for distributing and academically promoting Mimeixin. They will leverage the robust nationwide distribution network of the Sinopharm family in combination with its product portfolio to make Mimeixin available to as many patients as possible.

 

Deepening diverse collaboration to commercialize other products as well 

Luye Pharma will also deepen collaboration with Sinopharm Group and Sinopharm CNCM to promote products in other therapeutic areas as well, including the Central Nervous System (CNS), oncology, and cardiovascular diseases. This will expand the collaboration into a strategic partnership spanning the manufacturing, commercialization and sales of products by fully sharing resources and information with each other. 

Sinopharm Group is the supply chain leader of pharmaceutical products in China with more than 1,100 subsidiaries and 10,000 retail pharmacies. The group’s terminal network covers over 700,000 service providers. Sinopharm CNCM as a member of the group is a leading distributor of anesthetics and antipsychotics. Leveraging the Sinopharm family’s integrated supply chain for pharmaceutical products across China and its platform for comprehensive supply chain services, Luye Pharma is expected to increase the footprint of its other products as well, to reach more hospitals, retail pharmacies, DTP pharmacies and grassroots medical centers.

“We are committed to building an integrated ecosystem for pharmaceutical services spanning the entire value chain,” said Lian Wanyong, President of Sinopharm Group. “This partnership marks a major step for us to empower pharmaceutical innovation by leveraging our supply chain strength. Luye Pharma has several lines of internationally competitive products that can deliver significant clinical benefits. Starting from Mimeixin, we will further unlock the potential to collaborate with each other in multiple therapeutic areas and work out a new model for partnering across the pharmaceutical industry’s value chain.”

“I believe this partnership is win-win for all the three parties,” said Liu Yuetao, Chairman of Sinopharm CNMC. “Sinopharm CNCM has long been in the market for special anesthetics and antipsychotics, and has put into place an extensive distribution network and a robust operating system. We will leverage our strength to promote Mimeixin and take advantage of the Sinopharm family’s resources to make this and other quality medications more readily available to patients.”

“While launching many new drugs both at home and abroad in recent years, we have been actively working with industry leaders to accelerate the market penetration of these products through innovative and efficient commercial models,” said Ou Silang, Executive President of Luye Pharma Group. “As leading distributors of pharmaceutical products in China, Sinopharm Group and Sinopharm CNCM bring a wealth of expertise to the table with respect to channel management and terminal reach of products, especially the operation of special anesthetics and antipsychotics. This collaboration is a strategic move for us to enhance our commercial capabilities and reinforce our leadership in core therapeutic areas. By leveraging the strengths of each other, the three parties will be able to help make more innovative drugs available in clinical practice in a more efficient manner to meet the needs of patients.”  

 

---

About Luye Pharma Group

Luye Pharma Group is an international pharmaceutical company dedicated to developing, manufacturing, and selling innovative medications. With R&D centers in China, the U.S., and Europe, the company is an international leader in novel drug delivery systems such as microspheres, liposomes, and transdermal patches. It also has multiple innovative products in two categories: new chemical entities and antibodies. From 2021 to 2025, the company has had a total of 15 new drugs approved for marketing in one or multiple countries such as the U.S., China, Japan, and several European countries.

Luye Pharma has 8 manufacturing facilities worldwide, which follow internationally accepted, GMP-compliant quality management and control systems. To date, the company has launched over 30 products in the oncology, central nervous system, cardiovascular, and other therapeutic areas. It conducts business in over 80 countries and regions, including major pharmaceutical markets such as China, the U.S., Europe, and Japan, and also including fast-growing emerging markets.

About Sinopharm Group

Sinopharm Group Co. Ltd. (Sinopharm Group) is a nationwide pharmaceutical supply chain service provider under China National Pharmaceutical Group Co., Ltd. The company had its IPO on the Hong Kong Stock Exchange in September 2009 (stock code: 01099.HK). It has more than 1,100 subsidiaries, including two A-share companies: Sinopharm CNCM and Sinopharm Accord. Sinopharm Group has created an integrated ecosystem across the supply chain covering multiple areas including pharmaceutical products, medical devices, and chemical reagents with a focus on the distribution of pharmaceutical products and medical devices. Today, it is recognized as the top wholesaler and retailer of pharmaceutical products, medical devices, and health products as well as the leading supply chain service provider in China.

About Sinopharm CNCM

China National Medicines Corporation Ltd. (Sinopharm CNCM) is a leading nationwide distributor of pharmaceutical products and medical devices under Sinopharm Group Co. Ltd. (Sinopharm Group). The company had its IPO on the Shanghai Stock Exchange in November 2003 (stock code: 600511.SH). Headquartered in Beijing, the company operates a nationwide distribution network. It has four core businesses: Beijing-based direct-to-hospital sales, nationwide distribution of pharmaceuticals, sales of special anesthetics and antipsychotics, and sales of specialty medications. As a nationwide wholesaler for anesthetics and Class I antipsychotics, Sinopharm CNCM has been distributing such medications throughout the nation since the founding of the P.R.C. It’s a supplier of anesthetics and antipsychotics to more than 620 regional wholesalers, maintaining a dominant share in the distribution market.